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PR-LncRNA signature regulates 
glioma cell activity through 
expression of SOX factors
Sergio Torres-Bayona4, Paula Aldaz1,3, Jaione Auzmendi-Iriarte1, Ander Saenz-Antoñanzas1, 
Idoia Garcia1,2,3, Mariano Arrazola4,8, Daniela Gerovska6, Jose Undabeitia4, Arrate Querejeta4, 
Larraitz Egaña4, Jorge Villanúa4, Irune Ruiz3,4, Cristina Sarasqueta4,8, Enrique Urculo4,7, 
Marcos J. Araúzo-Bravo  2,6, Maite Huarte5, Nicolas Samprón3,4 & Ander Matheu1,2,3
Long non-coding RNAs (LncRNAs) have emerged as a relevant class of genome regulators involved 
in a broad range of biological processes and with important roles in tumor initiation and malignant 
progression. We have previously identified a p53-regulated tumor suppressor signature of LncRNAs 
(PR-LncRNAs) in colorectal cancer. Our aim was to identify the expression and function of this signature 
in gliomas. We found that the expression of the four PR-LncRNAs tested was high in human low-grade 
glioma samples and diminished with increasing grade of disease, being the lowest in glioblastoma 
samples. Functional assays demonstrated that PR-LncRNA silencing increased glioma cell proliferation 
and oncosphere formation. Mechanistically, we found an inverse correlation between PR-LncRNA 
expression and SOX1, SOX2 and SOX9 stem cell factors in human glioma biopsies and in glioma cells 
in vitro. Moreover, knock-down of SOX activity abolished the effect of PR-LncRNA silencing in glioma 
cell activity. In conclusion, our results demonstrate that the expression and function of PR-LncRNAs are 
significantly altered in gliomagenesis and that their activity is mediated by SOX factors. These results 
may provide important insights into the mechanisms responsible for glioblastoma pathogenesis.
Gliomas are relatively rare, around 350,000 people being diagnosed per year worldwide, but they are the most 
common primary brain tumors and, importantly, account for over 80% of malignant primary central nervous 
system tumors1. They have been classified into different grades of malignancy based on histopathological and 
clinical criteria, glioblastomas corresponding to the highest grade2. Glioblastoma is the most common and malig-
nant primary intracranial tumor in adults, with an incidence ranging from 1 to 5 cases per 100,000 people per 
year. Current therapy consists of maximal surgical tumor resection followed by concomitant radiotherapy and 
chemotherapy with temozolomide2. This therapy is only partially effective, however, and aggressive growth and 
recurrence frequently follows even after optimal treatment. In line with this, patients have an associated median 
survival of 12–15 months and only around 5% of patients survive to 3 years3,4. This dismal patient survival iden-
tifies glioblastoma as one of the most aggressive and fatal cancers overall. It is therefore necessary to identify 
strategies and targets for the early diagnosis and therapeutic treatment of gliomas.
Glioblastoma shows significant variability and heterogeneity at clinical, morphological, histopathological, 
molecular and cellular levels, and this heterogeneity goes a long way to explaining the poor prognosis2. Several 
studies have explored the genetic and molecular characteristics of this type of cancer, providing a high-resolution 
picture of the glioblastoma landscape, in turn, allowing the identification of different subtypes based on the 
molecular knowledge of the genome and transcriptome5–7. Nevertheless, high-throughput sequencing of whole 
genomes and transcriptomes found that less than 2% of the genome encodes proteins, whilst 75% is actively 
transcribed into noncoding RNAs8. Increasing evidence is demonstrating that frequent major genomic mutations 
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in cancer reside inside this vast majority of regions that do not encode proteins9. These genomic loci are often 
transcribed into long noncoding RNAs (LncRNAs)9.
LncRNAs are transcripts of more than 200 nucleotides that miss functional open reading frames and do 
not have functional protein-coding ability. Mechanistically, LncRNAs can fold into larger structures to provide 
higher potential for target recognition, which facilitates chromatin remodeling as well as transcriptional and 
post-transcriptional regulation10. Increasing evidence shows that the levels of LncRNAs are altered in multiple 
contexts and their deregulation facilitates the modulation of gene expression during both normal biological and 
pathological processes. Thus, mutations and dysregulations of lncRNAs contribute to the development of sev-
eral human complex diseases, including cancer11. In brain tumors, a microarray analysis identified over 1000 
LncRNAs differentially expressed in glioblastoma and healthy brain tissue12, with a similar quantity of LncRNAs 
overexpressed and silenced12. Additional studies confirmed differentially expressed LncRNAs in gliomas using 
further human tissues and also cell lines13,14. Notably, these altered LncRNA expression patterns have been corre-
lated with malignancy grade, patient survival and histological differentiation in human gliomas13,14. In line with 
this, the development of effective computational models predicted cancer associated-LncRNAs as biomarkers 
for glioma diagnosis, treatment and prognosis15,16. Moreover, abnormal LncRNA function plays critical roles in 
the development and progression of gliomas, controlling processes such as proliferation, apoptosis, self-renewal 
and migration13,14. These studies support the hypothesis that LncRNAs assume an important role in glioblastoma 
pathogenesis. Nevertheless, the exact functions in normal biological and disease processes have been reported for 
only a few LncRNAs in glioblastoma17,18.
Through genome-wide studies, we previously identified a set of LncRNAs, which are differentially expressed 
upon DNA damage in human colorectal cancer cells in response to active p5319. These LncRNAs, called 
p53-regulated LncRNAs (PR-LncRNAs), are required for the efficient binding of p53 to some of its well-known 
target genes and contribute to p53 pro-apoptotic and cell cycle regulatory functions19. Importantly, the expression 
of the PR-LncRNA signature is lower in colorectal cancer samples than healthy adjacent control tissue, suggesting 
that PR-LncRNAs might constitute a tumor-suppressor signature19. Since mutations on p53 are common and p53 
pathway is frequently deregulated in gliomas20, in this work, we characterized the expression and function of 
the PR-LncRNA signature, by studying the expression and clinical relevance of four members of this signature in 
human glioma samples of different grades and assessing the effect of loss of function in glioma cells.
Methods and Materials
Patients and tumor samples. Human glioma patient clinical information were obtained from the 
Donostia University Hospital. Human glioma samples were provided by the Basque Biobank for Research-
OEHUN (http://www.biobancovasco.org). The study included biopsies from 35 patients seen in San Sebastian, 
and diagnosed as primary glioblastoma grade IV according to the WHO criteria, 4 as a grade III and 4 as a low 
grade I-II. All study participants signed informed consent form approved by the Institutional Ethical Committee. 
The study was approved by the ethic committee of Hospital Donostia and all the experiments were performed in 
accordance with relevant guidelines and regulations.
RNA analysis. Total RNA was extracted with Trizol (Life Technologies). Reverse transcription was per-
formed using random priming and Maxima First Strand cDNA Synthesis Kit (ThermoFisher), according to 
the manufacturer’s guidelines. Quantitative real-time polymerase chain reaction (PCR) was performed using 
Absolute SYBR Green mix (Thermo Scientific) in a CFX384 Real-time thermal cycler (BioRad). Variations in 
input RNA were compensated for by subtracting the PCR threshold cycle values obtained for GAPDH.
Cell lines and cultures. Glioma cell lines U87-MG (U87), U373MG (U373), U251MG (U251) and A172 
purchased from the ATCC, were cultured in DMEM (Gibco) supplemented with 10% FBS (Gibco), 100 U/ml 
penicillin and 100 µg/ml streptomycin for traditional monolayer cultures. Patient-derived GNS166 and GNS179 
cell lines, kindly provided by Dr. Steven Pollard21, GB1 established by our group22, and oncospheres from glioma 
cell lines were cultured in DMEM/F-12 (Sigma) supplemented with N2, B27 supplements (Fisher) and growth 
factors (20 ng/ml basic fibroblast growth factor, and 20 ng/ml epidermal growth factor; Sigma) for oncosphere 
cultures22. Cells were maintained under standard conditions in humidified atmosphere of 5% CO2 at 37 °C.
Transfections with antisense oligonucleotides. The antisense oligonucleotide (ASO) sequences used 
in this study were designed and provided by ISIS Pharmaceuticals and the methodology has been previously 
described19. Cells were transfected with 50 nM of each ASO, using lipofectamine 2000 (Invitrogen) and inmuno-
fluorescence and mRNA studies were done 48 hours post-transfection.
Lentiviral infections. Lentiviral infections were performed as previously described23. For SOX knockdown, 
cells were infected with pLKO.1 shSOX1 and pLKO.1 shSOX9 or empty vector (obtained from Sigma). Infected 
cells were selected in the presence of 2 μg/ml puromycin and then maintained with 0.2 μg/ml puromycin (Sigma).
Oncosphere assays. For quantification studies, 7000 U87-MG cells/well were seeded in non-treated 6-well 
flat bottom plates and fresh media was added to the plates every 3 days. After 10 days, oncospheres were counted. 
Then, these oncospheres were disaggregated with accutase (Gibco), and same amount of cells were seeded for 
secondary oncospheres and maintained in culture for another 10 days.
Immunofluorescence. Immunofluorescence was performed following standard procedures24. The pri-
mary antibody was anti-phospho-histone-3 (PH3, 1:2000; Ab14955, Abcam), and the secondary antibody was 
anti-mouse Alexa Fluor 555 IgG (Invitrogen). Nuclear DNA was stained with Hoechst 33342 (Sigma). Pictures 
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Figure 1. PR-LncRNA expression in increasing glioma grade samples. (A) Comparison of PR-LncRNA 1, 
5, 10 and Unassigned 4 expression in low (grade II) and high-grade (III and IV) glioma (LGG and HGG 
respectively). (B) Expression of PR-LncRNA 1, 5, 10 and Unassigned 4 expression in grade II, III and IV gliomas. 
(C) Kaplan-Meier curve representing the survival of patients with grade II (n = 4), grade III (n = 4) and grade 
IV (glioblastoma) tumors (n = 35). (D) List of glioma biopsies with high (1) or low(0) (above or below median) 
expression of PR-LncRNA 1, 5, 10 and Unassigned 4 (E) Heat map of the prediction of a sample to be HGG or 
LGG using all different combinations (in columns) of expression of PR-LncRNAs as predictors. The colorbar 
on the top shows the probability of a sample to be HGG or LGG. The negative values are associated with the 
probabilities of LGG and the positive with the probabilities of HGG. Each row represents the probabilities for a 
patient. The column table to the right shows the real status of the sample: red for HGG and green for LGG. The 
optimal predictor variable combination for the discrimination analysis between LGG and HGG grade glioma is 
chosen as the one with lowest value of the Receiver Operating Characteristic (ROC) of the performance of the 
predictions and highest value of Accuracy, Specificity and Sensitivity, namely PR-LncRNA 1. (F) Heat map of 
the predictive value of a sample to be HGG (High) or LGG (Low) using the expression of PR-LncRNA 1 as the 
optimal predictor. The colorbar on the top shows the probability of a sample to be HGG. The table to the right 
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were taken with an Eclipse 80i microscope and processed with the NIS Elements Advances Research software 
(Nikon).
Discriminant analysis. The PCR expression of the four PR-LncRNAs were used to estimate the heuristic 
probability distribution functions of LGG and HGG conditions. The heuristic probability distribution functions 
of LGG and HGG conditions were predicted by fitting the corresponding log2 transformed signals using the gen-
eralized extreme value (GEV) model. The GEV model parameters: shape k, scale, σ and location µ, were estimated 
using the function fitdis of Matlab (MathWorksTM). To estimate the discrimination capability of each PR-LncRNA, 
we calculated the overlap of the LGG and HGG probability distribution functions (PDFs). For each x coordinate 
the overlap is the minumun of between the LGG and HGG PDFs. The PR-LncRNAs with best discrimination 
capabilities are those with smaller overlap between LGG and HGG PDFs. Next, we calculated the performance 
of all the possible combinations of selected PR-LncRNA using performance metrics of the Receiver Operating 
Characteristic (ROC), namely, the distance to the optimal point (0, 1) of the ROC space (D01), the accuracy, the 
specificity and the distance to the optimal point (0, 1) of the ROC space (D01) The D01 is calculated as D01 = (1 
− TPR2 + FPR2)0.5, were TPR and FPR are the true and false positive rates, respectively. Finally, the combination 
of PR-LncRNAs with smallest D01 and highest accuracy and specificity was selected as optimal predictor. We 
used the same set of samples for our prospective study to choose the optimal predictor and to make the prediction 
because of limited number of samples from LGG patients. Data processing and graphics were performed with 
functions developed in Matlab (MathWorksTM).
Results
Expression of PR-LncRNA signature decreases with glioma grade. To characterize the expres-
sion of the PR-LncRNAs in human glioma samples, we measured the expression of four of the PR-LncRNAs 
(PR-LncRNAs 1, 5 and 10 and Unassigned 4) in a set of biopsies including 4 low-grade gliomas (grade II), 4 
anaplasic gliomas (grade III) and 35 glioblastomas (grade IV) obtained from a cohort of patients from Donostia 
Hospital. First, we found that the levels of the four tested PR-lncRNAs were significantly higher in low-grade than 
high-grade gliomas (Fig. 1A). The analysis across the different tumor grades revealed that PR-lncRNA expression 
gradually decreased with the advance of glioma malignancy with the exception of PR-lncRNA-1 (Fig. 1B). In line 
with previous studies2, patient survival in the Donostia Hospital cohort decreased with advancing glioma grade 
(Fig. 1C), with a median survival of 77, 49 and 17 months in grades II, III and IV respectively.
Next, we studied whether the expression of PR-LncRNAs could form a signature in glioma samples and ana-
lyzed their putative association. Indeed, there were significant positive correlations between the expressions of 
the different PR-LncRNAs (p < 0.001) (Fig. 1D). Moreover, we developed a discriminant analysis method to study 
the predictive capabilities of the PR-LncRNA to predict low-grade or high grade gliomas. We found that the 
optimal combination of PR-LncRNAs is actually formed by a single PR-LncRNA, namely PR-LncRNA 1 (Fig. 1E). 
Finally, we used the optimal predictor PR-LncRNA 1 to perform the discriminant analysis on our sample set. We 
found that the optimal discriminator classified correctly 93% of the samples, with 100% for the case of high-grade 
glioma, and 25% for low grade (Fig. 1F). The low prediction rate of low-grade glioma is due to the lack of higher 
number of available patients (n = 4). These results show that PR-LncRNA levels do represent a signature, expres-
sion diminishing with glioma grade.
PR-LncRNA levels in glioma samples correlate with clinical characteristics. We performed cor-
relation analysis between the expression of the PR-LncRNAs and clinical data concerning Donostia University 
Hospital glioma cohort. We first analyzed the clinical data for the cohort. Patients were distributed homoge-
neously in terms of sex, and overall survival did not vary by sex (Table 1). Most of the patients were under 65 
years old and, notably, the risk of death was 3.5-fold higher in those who were ≥65 of years age (HR = 1.046, CI 
1.008–1.085) (Table 1). The majority of patients were autonomous (Karnofsky score ≥70) at the time of diagnosis, 
but a preoperative score <70 correlated with poorer outcome (P < 0.007) (Table 1). Finally, patients who under-
went complete surgical resection of the tumor (67%) survived for longer than those with subtotal extirpation 
(p = 0.022) (Table 1). On the other hand, we did not observe any significant correlation between patient survival 
and molecular markers such as MGMT, IDH1, ATRX, EGFR and p53 status (Table 2)
Next, we compared the expression of PR-LncRNAs with the aforementioned variables, finding that the means 
of the expression of the four PR-lncRNAs decreased from grade II to grade IV in female patients, and also in 
male with the exception of grade III (Fig. 2A). The trend of gradual decrease from lower to higher grade glioma 
is observed particularly in the expression of PR-LncRNA1 and 10 in female patients (Fig. 2B). Interestingly, for 
PR-LncRNA1, 5 and 10, the expression for female patients is higher than for male patients in grade III and glio-
blastoma (Fig. 2B, Table 3). These results indicate that PR-LncRNAs expression is sex related. On the contrary, 
we did not find significant differences in expression of PR-LncRNAs by age or pre-operative Karnofsky score 
(Table 3). Regarding tumor location, more than half of the tumors with high PR-LncRNAs were in frontal or tem-
poral locations, the right hemisphere and a non-eloquent area (Table 3). Similar percentages had tumor volumes 
greater than 50 mm3 and a magnetic resonance imaging perfusion parameter higher than 6 (Table 3). When 
comparing the expression of PR-LncRNAs with MGMT methylation status, and Ki67, IDH1, ATRX and EGFR 
of the heatmap shows: S, real status of the sample; P, predicted status of the sample; C, comparison between the 
real and the predicted status. Red color is used for HGG, green for LGG, and white when there is no coincidence 
between the real and the predicted status using this optimal predictor, PR-LncRNA 1Asterisks (*) indicate 
statistical significance (p < 0.05).
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expression, we did not detect any significant associations (Fig. 2C). We observed that majority of samples with 
high levels of PR-LncRNAs had wild type p53, while over 50% of cases with low expression of PR-LncRNAs had 
mutated p53 genes, although this difference was not statistically significant (Fig. 2C).
Finally, we compared PR-LncRNA expression with overall glioblastoma patient survival and we did not 
observe significant correlations, although we noticed that patients with high levels had longer overall survival for 
all PR-LncRNAs (Fig. 2D). The mean survival rates of the subgroup of patients with high levels of PR-LncRNAs 
1, 5 and 10, and Unassigned 4 were 20, 19.8, 18.1 and 21.9 months respectively, and notably, the survival rates 
were lower when biopsies presented low levels of these PR-LncRNAs: 16.3, 17, 17.2 and 16.6 months respectively 
(Fig. 2D). These data indicate a 2–4 month longer survival in patients with higher PR-LncRNA levels. In summary, 
these results show that the expression of PR-LncRNAs is altered in glioblastoma samples and low levels of these 
ncRNAs tend to correlate with characteristics linked to increased malignancy.
Clinical/pathological 
characteristics
Number of 
patients
Low grade 
(I-II)
Anaplasic 
(III)
Glioblastoma 
(IV)
P Value 
Survival
Glioma Grade 43 4 4 35 0.0031
Sex 43
Male 2 2 17 NS
Female 2 2 18
Age, years 43
≥65 4 2 7
<65 0 2 28
Localization 43
Frontal 1 2 16 NS
Temporal 1 13 NS
Parietal 1 2 NS
Other 3 4 NSNS
Multifoci 5
Right 43 2 4 25 0.000***
Left 13 NS
Bilateral 2 5 NS
Eloquent 43 1 1 12 0.001***
Ventricular contact 43 2 3 20 NS
Radiological Characteristics
Tumor Volume
≥50 43 −0.069
<50 1 3 20
Perfusion 3 1 15
≥6 39 0 0 24 −0.706
<6 0 4 11
Karnofsky score 43
≥70 3 4 28 0.007**
<70 1 0 7
Resection 43
Total 4 3 22 0.022*
Subtotal 0 1 13
Table 1. Clinical and radiological characteristics of the glioma cohort from Donostia Hospital.
Molecular characteristics TOTAL
Low grade 
(I-II) Anaplasic (III)
GBM 
(IV)
P Value vs 
Survival
Genes
P53 expression 38 1/1 3/3 23/34 NS
High EGFR 35 ND ND 22/35 NS
Mutated IDH1 33 ND 2/4 0/29 NS
ATRX loss 18 ND ND 13/18 NS
MGMT methylation 11 1/1 3/4 3/6 NS
Ki67 index≥4 40 0/4 3/3 33/33 NS
Table 2. Molecular characteristics of the glioblastoma cohort from Donostia hospital.
www.nature.com/scientificreports/
6SCIENtIFIC REPORTS |  (2018) 8:12746  | DOI:10.1038/s41598-018-30836-5
Silencing of PR-LncRNAs increases cellular proliferation and stem cell properties. In order to 
characterize the impact of PR-LncRNAs at the cellular level, we inhibited the activity of PR-LncRNAs by trans-
fecting two specific ASOs for PR-LncRNA1 and 10 respectively. Quantitative reverse transcription PCR showed 
a significant decrease in the expression of the specific PR-LncRNA (Fig. 3A,B). Importantly, when we compared 
the proliferative potential of control and PR-LncRNA-silenced glioma cells, we detected that the number of 
phospho-histone-3 (PH-3) positive cells was markedly higher in cells transfected with the ASOs for PR-LncRNA1 
Figure 2. Correlation between PR-LncRNA expression and patient clinical characteristics. (A) Violin plot 
associated to the distribution of the expression of the PR-LncRNAs in gliobastoma (IV), anaplastic (III) and low-
grade glioma (II) separated by sex (M - male, F - female). The + denote the mean values of the distributions and 
the black dots are the expression values. (B) Heat map of the expression of the studied PR-LncRNAs separated 
by sex. Redder color corresponds to higher expression. The colorbar on the top codifies the expression level. (C) 
Correlation between expression of PR-LncRNAs and molecular markers frequently altered in glioma, namely, 
p53, Ki67, EGFR, IDH1, ATRX and MGMT. (D) Median overall survival stratified by level of each of the PR-
LncRNAs studied.
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and 10 (Fig. 3C,D). Indeed, 3.05% of controls were positive for PH3 compared to 4.9 and 5.38 for PR-LncRNA1 
ASOs and 6.84 and 6.1 for PR-LncRNA10 ASOs. Moreover, the expression of p53 downstream targets such as 
p21cip, BAX and SerpinB5 was lower in cells transfected with ASOs for PR-LncRNA1 and 10 (Fig. 3E). These results 
support at molecular level the anti-proliferative activity of PR-LncRNAs and, since U87-MG cells present p53 
wild-type status, the link with p53 pathway.
Glioma stem cells (GSCs) are a subpopulation of cells linked to glioma malignancy, progression and postu-
lated as therapeutic targets25. We observed that the expression of PR-LncRNAs, particularly PR-LncRNA1 and 5, 
was lower in patient derived GSC lines (GNS166, GNS179 or GB1) than in conventional glioma cell lines such 
as U87MG, U251 or A172 (Fig. 3F). Moreover, the ability to form oncospheres was significantly elevated in cells 
with silencing of PR-LncRNA1 and 10 expression (Fig. 3G). This idea was further corroborated as cells with 
PR-LncRNA1 and 10 silencing formed significantly more secondary oncospheres (Fig. 3H). In summary, these 
results demonstrate that PR-LncRNAs regulate the activity of glioma cells.
SOX factors mediate PR-LncRNAs activity. We and others have previously described several regula-
tors of GSCs activity such as members of the SOX family, PML and STAT322,24–29. Therefore, we studied whether 
they were related to PR-LncRNAs activity. Correlation analysis in human biopsies determined that there is a 
strong inverse correlation between expression of the different PR-LncRNAs and that of SOX1, SOX2 and SOX9 
(Fig. 4A,B). The inverse association in human biopsies was especially strong for SOX1 and SOX9 (Fig. 4B). 
Similar correlation was observed in glioma cells and GSCs, the latter expressing high levels of SOX members 
(Fig. 4C). To further investigate the link between PR-LncRNAs and SOX members, we studied the expression of 
the latter in cells transfected with PR-LncRNA1 and 10 ASOs. Interestingly, we observed that specially SOX1 and 
SOX2 expression was elevated in those cells (Fig. 4D), suggesting that these members of the SOX family may be 
mediators of PR-LncRNA activity in gliomas. On the contrary, cells with overexpression and silencing of SOX1, 
SOX2 and SOX9 do not present a clear pattern of decreased and increased levels of PR-LncRNAs respectively 
(Fig. Suppl 1). These results indicate that PR-LncRNA act upstream SOX family members to regulate glioma cell 
Clinical/pathological 
characteristics
Total 
cases #
PR-LncRNA Expression
PR-LncRNA 1 PR-LncRNA 5 PR-LncRNA 10
High Low P Value High Low P Value High Low P Value
Sex
Male 43 22 15 6 ns 13 8 0.05* 14 7 ns
Female 21 20 2 19 3 19 3
Age, years
>65
43
13 11 2
ns
10 3
ns
10 3
ns
<65 30 24 6 21 9 23 7
Localization
Frontal 20 14 6 ns 12 8 0.04* 20 8 0.019*
Temporal 18 17 1 ns 16 2 ns 17 1 0.021*
Parietal 6 4 2 ns 3 3 ns 4 2 ns
Other 10 10 0 ns 10 0 0.034* 10 0 0.048*
Multifoci 5 4 1 ns 4 1 ns 5 0 ns
Right 23 19 4 ns 16 7 ns 17 6 ns
Left 17 14 3 ns 14 3 ns 14 3 ns
Bilateral 3 2 1 ns 2 1 ns 2 1 ns
Eloquent 11 9 2 ns 8 3 ns 8 3 ns
Ventricular contact 18 16 2 ns 16 2 0.065* 16 2 ns
Radiological Characteristics
Volume
>50 43 24 19 5 ns 17 7 ns 17 7 ns
<50 19 16 3 15 4 16 3
Perfusion
>6 39 24 19 5 ns 17 7 ns 17 7 ns
<6 15 12 3 11 4 12 3
Karnofsky score
>70 43 35 27 8 ns 24 11 ns 26 9 ns
<70 8 8 0 8 0 7 1
Resection
Total 43 29 23 6 ns 21 8 ns 22 7 ns
Subtotal 14 12 2 11 3 11 3
Table 3. Correlation between PR-LncRNA and clinical characteristics in the glioma cohort.
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activity. To further test this idea, SOX1 and SOX9 expression was knocked-down in cells transfected with ASOs 
for PR-LncRNA1 and 10. Interestingly, silencing of SOX1 or SOX9 abolished the increase in proliferation and 
oncosphere formation promoted by PR-LncRNA1 and 10 inhibition (Fig. 4E,F), experimentally demonstrating 
that SOX factors are critical mediators of PR-LncRNA activity.
Discussion
LncRNAs are a novel group of genome regulators for which there is growing evidence linking their altered 
expression to a variety of cancers. In this work, we studied the expression and function of a recently described 
PR-LncRNA signature19 in gliomas. We found that the expression of this set of PR-LncRNAs is altered in samples 
from different glioma subtypes. Specifically, their levels are higher in low-grade than in high-grade gliomas, and 
decrease as the grade increases, with the lowest levels observed in glioblastoma samples. These results are in 
Figure 3. PR-LncRNA1 and 10 silencing leads to increased proliferation and stemness. U87-MG cells were 
transfected with specific ASOs for the PR-LncRNAs indicated. (A,B) Transfected cells were examined for 
PR-LncRNA1 and PR-LncRNA10 expression by quantitative reverse transcription polymerase chain reaction 
(n = 4). (C) Representative immunofluorescence of P-H3 in U87MG cells under the conditions indicated. (D) 
Quantification of the number of P-H3 positive cells under the conditions indicated (n = 4). (E) Quantification 
of mRNA levels of p21cip, Bax and SerpinB5 in cells transfected with ASOs for PR-LncRNA1 and 10 and 
compared to cells with a control ASO (F) Expression of PR-LncRNA 1,5 and 10 in indicated conventional cell 
lines (U87-MG, U251, U373 and A172) and glioma stem cells (GNS166, GNS179 and GB1) (G) Quantification 
of primary oncospheres formed in ASO-transfected cells after 10 days in culture (n = 3). (H) Quantification of 
number of secondary oncospheres generated from disaggregating primary oncospheres in ASO-transfected and 
control cells. Numbers were assessed after 10 days in culture (n = 3). Asterisks (*,**and ***) indicate statistical 
significance (p < 0.05, p < 0.01, and p < 0.001, respectively).
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agreement with the previous study in which this set of PR-LncRNAs was found to be downregulated in colorectal 
cancer samples compared to levels in healthy control tissue19.
Clinically, we observed that patients with low levels of PR-LncRNAs had tumors in frontal or temporal sites, 
the right hemisphere and areas in contact with ventricles, characteristics, which have been associated with 
shorter patient survival30,31. In line with this, the subset of biopsies with low levels of the PR-LncRNAs studied 
overlapped with the subgroup of patients with the lowest median overall survival, although the association was 
Figure 4. SOX stem cell factors mediate activity of PR-LncRNAs. (A) Analysis of the association between 
expression of PR-LncRNAs and stem cell factors in human glioma samples, showing there is a significant 
inverse correlation between PR-LncRNAs and SOX members. (B) Correlation between PR-LncRNAs and SOX 
factors in human glioma samples. Spearman Correlation Rho is −0,546 (**), −0,221 and −0,342 (*) for SOX1, 
SOX2 and SOX9 with PR-LncRNA1. It is −0,670 (***), −0,151 and −0,285 (*) for SOX1, SOX2 and SOX9 
with PR-LncRNA5. Finally numbers are −0,521 (**), −0,171 and −0,230 for SOX1, SOX2 and SOX9 with PR-
LncRNA10. (C) Violin plots associated to the expression distribution of the PR-LncRNAs (green circles) and 
SOX factors (red circles). Values in indicated cells are relative to expression of each transcript in U87-MG cells. 
The + denote the mean values of the distributions and the black dots are the expression values. (D) Quantitative 
reverse transcription polymerase chain reaction of SOX1, SOX2 and SOX9 in U87-MG control and transfected 
with ASOs. Data represents the average of 3 independent experiments. (E) Quantification of the number of 
P-H3 positive cells in U87-MG cells transfected with indicated ASOs and lentivirally infected with shSOX1, 
shSOX9 or empty vector (pLKO) (n = 2). (F) Quantification of the number of formed oncospheres in U87 cells 
transfected with indicated ASOs and lentivirally infected with shSOX1, shSOX9 or empty vector (pLKO) (n = 2). 
P values were determined by Student’s t test. Asterisks (*,**) indicate statistical significance (p < 0.05 and 
p < 0.01).
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not significant, likely due to the small size of the cohort. Building on the association of downregulated levels of 
PR-LncRNAs with poor clinical prognosis, in the previous study in colon cancer19, our findings indicate that the 
signature of PR-LncRNAs is not exclusive to human colorectal cancer and suggest that the pattern of expression of 
these Lnc-RNAs might constitute a tumor suppressor signature in different types of cancer. This activity might be 
influenced by the gender since female patients present higher levels of PR-LncRNAs particularly in grade III and 
glioblastomas. These results further support the link of PR-LncRNAs and poor prognosis because there is evidence 
that female patients have a survival advantage and live longer than males in glioblastoma32.
There is an increasing interest among scientists to generate tools to predict clinical phenotypes and tumor 
progression in order to identify biomarkers and to better design patient treatment33. Indeed, there have been 
generated computational models for lncRNA-cancer association prediction11,34. In our study, we generated com-
putational models in order to determine whether the expression of PR-LncRNAs could predict glioma grade pro-
gression. However, the PR-LncRNA signature only discriminated partially between low and high-grade gliomas 
due to the very low amount of low-grade cases.
Deregulation of the p53 pathway is well known to occur and play a major role in the development and pro-
gression of several types of cancer including glioblastoma20. The PR-LncRNA signature was originally identi-
fied as p53-regulated LncRNAs19. We did not detect a statistically significant association between p53 status and 
PR-LncRNA expression, although most of the biopsies with high levels of PR-LncRNAs were positive for wild-type 
p53 in immunohistochemical analysis, and several p53 downstream targets were decreased in U87-MG cells with 
PR-LncRNAs silencing. It is important to indicate that the PR-LncRNA signature was identified as p53 regulated 
upon DNA damage in the HCT116 colorectal cancer cell line19. It is reasonable to surmise that: (i) the response 
of the PR-LncRNAs might be different in clinical samples and cell lines and also upon stressful conditions in vitro; 
(ii) the activity and regulation of the signature might be partially different within the different types of cancer; and 
(iii) some of the PR-LncRNAs might be regulated in a p53-independent manner, given that only around ~3% of 
the PR-LncRNAs altered by DNA damage in colorectal cells were directly bound by p5319. Further, the association 
study between p53 protein levels and PR-LncRNAs in human colorectal cancer biopsies has yet to be established. 
Therefore, further studies need to be conducted with a larger number of samples and in different types of cancer 
to decipher the link between p53 and PR-LncRNAs in clinical samples. Independently of all these possibilities, our 
observations confirm the previous results and link expression of the PR-LncRNA signature with poor prognosis 
and increased malignancy in clinical samples.
In agreement with the results obtained in clinical practice and in colorectal cancer cells19, functional studies 
in glioma cells demonstrated that PR-LncRNA silencing increased the proliferative capacity of cells supporting 
the potential role of PR-lncRNAs as a tumor suppressor signature in glioma. This effect was regulated, at least in 
part, by p53 pathway and SOX members. Importantly, we also observed that PR-LncRNAs regulate the activity 
of glioma stem cells. Indeed, silencing of the PR-LncRNAs1 and 10 significantly increased the oncosphere for-
mation ability of glioma cells and their self-renewal potential. Moreover, the levels of PR-LncRNAs were lower in 
patient derived glioma stem cell populations than in differentiated conventional glioma cell lines. Of note, there 
is a small proportion of LncRNAs that have been shown to regulate the activity of the subpopulation of glioma 
stem cells13,35,36, and little is known concerning the underlying molecular mechanisms regulating this activity37. 
Therefore, we tried to identify the downstream mechanism of this action revealing that PR-LncRNAs regulate the 
expression of SOX2 SOX9 and especially SOX1, members of the SOX family transcription factor and stem cell reg-
ulators38. It is noteworthy that high levels of these genes have been previously linked to glioma poor prognosis and 
overall shorter survival in clinical practice and glioma stem cell population at the cellular level22,24,27,39. Thus, we 
observed that expression of PR-LncRNA was significantly inversely correlated with that of SOX2, SOX9 and SOX1 
in human clinical biopsies and in cell cultures in vitro. Moreover, experiments in vitro revealed that their levels, 
especially of SOX1 and SOX2, were significantly elevated in PR-LncRNA silencing cells and that knock-down of 
SOX1 and SOX9 expression dramatically reduced the pro-oncogenic activities promoted by PR-LncRNA silencing 
in glioma cells. Together, these results postulate the SOX family as novel and critical mediator of the PR-LncRNAs 
activity. In line with these results, gain and loss of function studies demonstrated that SOX members regulate 
glioma stem cell function as well as glioma cell proliferation and tumorigenic activity27.
It has been postulated that understanding the function and mechanism by which LncRNAs participate in 
glioma stem cell activity might facilitate development of therapeutic strategies for the treatment of the disease14. 
In summary, our study identified a novel LncRNA signature associated with glioma progression and malignancy 
in the clinic and revealed the tumor suppressor role played by these LncRNAs at cellular level. Our data also 
revealed that members of the SOX family of stem cell regulators, in particular the recently described SOX124, 
are critical mediators of their activity. These results unravel the expression and function of the PR-LncRNAs in 
glioma pathobiology, postulating them as novel biomarkers in glioma diagnosis, especially for female patients, as 
well as potential therapeutic targets.
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